Technical Information

InertSearch (Application Library)

Index

Application

Micro GC

Document No. Index

LB013 - 100 of Application List

No. Description Column
LB013 Analysis of Iohexol and Iopamidol InertSustain C18
LB014 Analysis of Ergosterol(InertSustain C18) InertSustain C18
LB015 Analysis of Ergosterol(Inertsil ODS-4) Inertsil ODS-4
LB016 Analysis of Iminoctadine InertSustain C18
LB017 Analysis of Furosemide(Under the Condition of Japanese Pharmacopoeia) Inertsil WP300 C18
LB018 Analysis of Potassium ferricyanide and Potassium ferrocyanide InertSustain C18
LB019 Analysis of Losartan Potassium and Hydrochlorothiazide Inertsil C8-4
LB020 Analysis of Losartan Potassium and Hydrochlorothiazide InertSustain C8
LB021 Analysis of Valsartan and Hydrochlorothiazide InertSustain C18
LB022 Analysis of Losartan potassium and Valsartan InertSustain C18
LB023 Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Tablets) InertSustain C18
LB024 Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Tablets) InertSustain C18
LB025 Analysis of Atorvastatin Calcium (Under the Condition of Japanese Pharmacopoeia, Atorvastatin Calcium Hydrate) InertSustain C18
LB026 Analysis of Pitavastatin Calcium InertSustain C18
LB027 Analysis of Pitavastatin Calcium InertSustain C18
LB028 Analysis of Pitavastatin Calcium InertSustain C18
LB029 Analysis of Pitavastatin Calcium InertSustain C18
LB030 Analysis of Vitamin K (InertSustain C8) InertSustain C8
LB031 Analysis of Preservatives and Sweetener InertSustain Phenyl
LB032 Analysis of Malto oligosugars InertSustain NH2
LB033 Analysis of Vitamin E InertSustain NH2
LB034 Analysis of Nucleotides InertSustain NH2
LB035 Analysis of Terbinafine HCl (InertSustain C18) (Under the Condition of Japanese Pharmacopoeia) InertSustain C18
LB036 Analysis of Terbinafine HCl (Inertsil ODS-3) (Under the Condition of Japanese Pharmacopoeia) Inertsil ODS-3
LB037 Analysis of Terbinafine HCl (Inertsil ODS-4) (Under the Condition of Japanese Pharmacopoeia) Inertsil ODS-4
LB038 Analysis of Chlorantraniliprole (InertSustain C18) InertSustain C18
LB039 Analysis of Phospholipids (InertSustain C18) InertSustain C18
LB040 Analysis of Phospholipids (InertSustain C8) InertSustain C8
LB041 Analysis of Phospholipids (Inertsil ODS-4) Inertsil ODS-4
LB042 Analysis of 18Drugs(InertSustain C18 2um) InertSustain C18
LB043 Analysis of 18Drugs(InertSustain C18 HP) InertSustain C18
LB044 Analysis of Pyridine derivatives (InertSustain C8) InertSustain C8
LB045 Analysis of Preservatives (Inertsil ODS-4) Inertsil ODS-4
LB046 Analysis of Preservatives (Inertsil ODS-4) Inertsil ODS-4
LB047 Analysis of Preservatives (Inertsil ODS-4) Inertsil ODS-4
LB048 Analysis of Preservatives (Inertsil ODS-4) Inertsil ODS-4
LB049 Analysis of Pioglitazone(Inertsil ODS-4) Inertsil ODS-4
LB050 Analysis of Pioglitazone(Inertsil ODS-4) Inertsil ODS-4
LB051 Analysis of Amlodipine (Inertsil ODS-4) Inertsil ODS-4
LB052 Analysis of Valsartan (Inertsil ODS-4) Inertsil ODS-4
LB053 Analysis of Alkylbenzene sulfonate (Inertsil ODS-3) Inertsil ODS-3
LB054 Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia) InertSustain C8
LB055 Analysis of Olopatadine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) InertSustain C8
LB056 Analysis of Olopatadine hydrochloride(Under the Condition of Japanese Pharmacopoeia, Olopatadine hydrochloride Tablets) InertSustain C8
LB057 Analysis of Acetylcysteine (Under the Condition of Japanese Pharmacopoeia 16) Inertsil ODS-4
LB058 Analysis of Amlodipine Besilate (Under the Condition of Japanese Pharmacopoeia, Amlodipine Besilate Tablets) InertSustain C18
LB059 Analysis of Quetiapine Fumarate (Under the Condition of the Japanese Pharmacopoeia) Inertsil C8-4
LB060 Analysis of Quetiapine Fumarate (Under the Condition of the Japanese Pharmacopoeia, Quetiapine Fumarate Tablets) Inertsil C8-4
LB061 Analysis of Sarpogrelate Hydrochloride (Under the Condition of Japanese Pharmacopoeia 16) Inertsil ODS-2
LB062 Analysis of Cetiridine hydrochloride (Under the Condition of Japanese Pharmacopoeia, Cetiridine hydrochloride Tablets) Inertsil C8-3
LB063 Analysis of Tranilast (InertSustain C18)(Under the Condition of the Japanese Pharmacopoeia) InertSustain C18
LB064 Analysis of Tranilast (Inertsil ODS-4)(Under the Condition of the Japanese Pharmacopoeia) Inertsil ODS-4
LB065 Analysis of Brotizolam(Under the Condition of the Japanese Pharmacopoeia) Inertsil WP300 C8
LB066 Analysis of Mosapride Citrate Tablets (Under the Condition of Japanese Pharmacopoeia 16) InertSustain C18
LB067 Analysis of Aripiprazole InertSustain C18
LB068 Analysis of Olmesartan medoxomil InertSustain C18
LB069 Analysis of Rosuvastatin Calcium InertSustain C18
LB070 Analysis of 13 drugs for NSAIDs InertSustain C18
LB071 Analysis of Esomeprazol (InertSustain C18) InertSustain C18
LB072 Analysis of Ezetimibe (Inertsil C8-4) Inertsil C8-4
LB073 Analysis of Irbesartan (Inertsil ODS-4) Inertsil ODS-4
LB074 Analysis of Rabeprazol (InertSustain C18) InertSustain C18
LB075 Analysis of Venlafaxine (InertSustain C18) InertSustain C18
LB076 Analysis of 4 Pesticides (InertSustain C18) InertSustain C18
LB077 Analysis of 4 Pesticides (InertSustain Phenyl) InertSustain Phenyl
LB078 Analysis of 4 Pesticides (Inertsil ODS-4) Inertsil ODS-4
LB079 Analysis of 4 Pesticides (Inertsil ODS-3) Inertsil ODS-3
LB081 Analysis of Fucoxanthin (Inertsil ODS-3) Inertsil ODS-3
LB082 Analysis of Sertraline hydrochloride (Under the Condition of European Pharmacopoeia 7.0) Inertsil ODS-3
LB083 Analysis of Ranitidine hydrochloride (Under the Condition of Japanese Pharmacopoeia 16) ODS
LB084 Analysis of Olmesartan medoxomil (Under the Condition of United States Pharmacopeia 35-NF30) InertSustain C18
LB085 Analysis of Olmesartan medoxomil (Under the Condition of the Japanese Pharmacopoeia) Inertsil ODS-2
LB086 Analysis of Naftopidil (Under the Condition of the Japanese Pharmacopoeia) InertSustain C18
LB087 Analysis of Naftopidil (Under the Condition of the Japanese Pharmacopoeia, Naftopidil Tablets) InertSustain C18
LB088 Analysis of Pre-column Derivatized Amino Acids Inertsil ODS-4
LB089 Analysis of Phenylenediamine Inertsil ODS-3
LB091 Analysis of Sinigrin (Inertsil ODS-3) Inertsil ODS-3
LB092 Analysis of Edaravone (Under the Condition of Japanese Pharmacopoeia) Inertsil ODS-3
LB093 Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) InertSustain C8
LB094 Analysis of Pranlukast hydrate (Under the Condition of the Japanese Pharmacopoeia) InertSustain C8
LB095 Analysis of Edaravone Injection (Under the Condition of the Japanese Pharmacopoeia) Inertsil WP300 C18
LB096 Analysis of p-Hydroxybenzoic acid methyl ester (Under the Condition of Japanese Pharmacopoeia) Inertsil ODS-4
LB097 Analysis of p-Hydroxybenzoic acid ethyl ester (Under the Condition of Japanese Pharmacopoeia) Inertsil ODS-4
LB098 Analysis of p-Hydroxybenzoic acid n-propyl ester (Under the Condition of Japanese Pharmacopoeia) Inertsil ODS-4
LB099 Analysis of p-Hydroxybenzoic acid n-butyl ester (Under the Condition of Japanese Pharmacopoeia) Inertsil ODS-4
LB100 Analysis of p-Hydroxybenzoic acid n-butyl ester (Under the Condition of Japanese Pharmacopoeia) Inertsil ODS-4